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Dear Editor, 
We read with interest the study published by Tang and coll.1 in a recent issue of the Journal of 
Thrombosis and Haemostasis. In this retrospective analysis, conducted at the Tongji Hospital  of 
Wuhan, China, it is reported that heparin treatment reduces mortality in subjects affected by severe 
COVID-19 who have “sepsis-induced coagulopathy”. The definition of severe COVID-19 was the 
presence of at least one of following: respiratory rate ≥30 breaths /min; arterial oxygen saturation 
≤93% at rest; PaO2/FiO2 ≤300 mmHg. The Authors of this study also reported that, among subjects 
not treated with heparin, mortality raised according with D-dimer levels. Of note, patients that 
received heparin in this study were mostly treated with enoxaparin, at the thromboprophylactic dose 
of 40-60 mg/day, for at least 7 days. 
We are surprised that only 22.0% of the population analyzed by Tang and coll. (99 patients on a 
total of 449) received anticoagulant therapy for the prevention of venous thromboembolism (VTE). 
Indeed, patients hospitalized for COVID-19, and in particular those with a “severe” disease, are by 
definition at increased risk for VTE. Considering that these patients had respiratory failure, were 
likely bedridden for oxygen supplementation, and had an acute respiratory infection, their PADUA 
score 2 was necessarily ≥4, without even taking into account the possibility that some of them could 
have cancer, history of previous VTE, and age >70 years. Based on this, it is possible to 
hypothesize that, among the 350 patients that did not receive heparin (or were treated for less than 7 
days), some developed pulmonary embolism (EP), which could have contributed to mortality in this 
group. Such hypothesis is strengthened by the fact that mortality correlates with D-dimer levels 
among heparin non-users, although we are aware that high D-dimer levels may be due to many 
factors in COVID-19 patients and do not necessarily depend on the presence of VTE. 
It would be helpful to know whether heparin users and non-users differed in terms of PADUA 
score. Also, it would interesting if the Authors could retrospectively reanalyze their study 
population to determine how many patients were screened for VTE by ultrasonography of the legs 
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and/or CT scan pulmonary angiography, and assess whether VTE was more frequent among 
subjects who did not receive thromboprophylaxis with heparin, compared to heparin-treated 
individuals.  
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